ArticleCirculation reports2026
Long-Term Outcomes of Primary Cardiac Tumors by Histological Subtype.
Article in Circulation reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary cardiac tumors are rare, and the prognostic impact of their histological subtypes remains poorly understood. We assessed the clinical outcomes of benign and malignant tumors using long-term follow-up data from pathologically confirmed cases. Methods and Results: We retrospectively analyzed 42 consecutive patients diagnosed with primary cardiac tumors between 2007 and 2022 at a single center. Among them, 41 patients who underwent surgical resection were followed longitudinally and included in the present study. Clinical features, tumor distribution, and outcomes were assessed by histological type, with particular focus on long-term prognosis. Histological diagnoses were confirmed in each case. Myxomas accounted for 73% (n=30), diffuse large B-cell lymphomas (DLBCLs) for 7% (n=3), and other benign tumors for 20% (n=8) of cases. Myxomas were predominantly located in the left atrium and showed excellent long-term outcomes, with no recurrence or tumor-related deaths over a median follow-up of 12.8 years. In contrast, all patients with DLBCL had right-sided tumors and died within 2 years due to disease progression despite surgery and chemotherapy. Kaplan-Meier analysis showed significant differences (P<0.001) in survival among tumor types, with DLBCL showing uniformly poor outcomes. Conclusions: Benign cardiac tumors had favorable outcomes, with myxomas showing a particularly excellent prognosis. In contrast, malignant tumors were uniformly associated with early death. Histological subtype may be associated with survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.